

EVENITY (romosozumab-aqqg)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

Postmenopausal women with osteoporosis

AND ALL of the following:

- a. Inadequate treatment response, intolerance, or contraindication to bisphosphonate therapy **OR** Prolia (denosumab)
- b. Pre-existing hypocalcemia must be corrected prior to initiating therapy
- c. Patient has T-score below -2.5 **OR** patient is at high risk for bone fracture(s) (prior osteoporotic fracture or multiple risk factors for fracture)
- d. NO myocardial infarction or stroke within the preceding year
- e. NO cumulative therapy with Evenity for longer than 12 months
- f. **NO** concurrent therapy with another Prior Authorization (PA) medication for osteoporosis (see Appendix 1)

Prior - Approval Limits

Quantity 6 prefilled syringes per 90 days

Duration 12 months

Prior – Approval Renewal Requirements

None

Prior - Approval Renewal Limits

None



Federal Employee Program.

EVENITY (romosozumab-aqqg)

Appendix 1 - List of PA Osteoporosis Medications

Generic Name	Brand Name
abaloparatide	Tymlos
denosumab	Prolia
romosuzumab-aqqg	Evenity
teriparatide	Bonsity
teriparatide	Forteo
teriparatide	Teriparatide